Prostate carcinoma: immunostaging and adjuvant immunotherapy with BCG.
Thirty-three patients with histologic diagnosis of adenocarcinoma of the prostate were entered into separate protocols: 1) immunostaging, and 2) BCG adjuvant immunotherapy. Immunostaging is a new method of assessing patients immunologically prior to and after immunotherapy. Thirty of these patients were immunostaged with the use of humoral and cellular immune parameters. A positive correlation was noted between the patient's immunostage and the clinical stage of his cancer. The 33 patients with a histologic diagnosis of adenocarcinoma of the prostate were entered into an ongoing protocol of adjuvant BCG immunotherapy in addition to conventional therapy (19 patients received BCG and 14 served as controls). The patients receiving BCG had a longer mean survival time; minimal morbidity and no mortality resulted from this therapy.